- Home
- RERE vs ABSI Comparison
RERE vs ABSI Comparison
Compare RERE & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | ABSI |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.0M | 997.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RERE | ABSI |
|---|---|---|
| Price | $4.30 | $7.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.96 |
| AVG Volume (30 Days) | 773.8K | ★ 4.3M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | $25.70 | $215.96 |
| Revenue Next Year | $22.93 | $319.10 |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.07 | $2.24 |
| 52 Week High | $6.47 | $12.06 |
Technical Indicators
Market Signals| Indicator | RERE | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 34.84 |
| Support Level | $3.96 | $2.56 |
| Resistance Level | $4.35 | $12.06 |
| Average True Range (ATR) | 0.17 | 0.71 |
| MACD | 0.04 | -0.44 |
| Stochastic Oscillator | 92.37 | 5.44 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.